Rodatristat ethyl decreases the level of 5-HT and significantly reduces pulmonary arterial hypertension. Rodatristat ethyl is a first-in-class oral tryptophan hydroxylase 1 Inhibitor.

Rodatristat ethyl (100 or 200 mg/kg; p.o.; once daily; for 28 days; male Sprague-Dawley rats) treatment reduces erum, gut, and lung 5-HT levels in a dose-dependent manner. It also obviously reduces pulmonary arterial pressure and pulmonary vessel wall thickness and occlusion in male rats with monocrotaline [1].

1673571-51-1

C29H31ClF3N5O3

590.04

KAR5585

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years